MedTrace Logo

A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects

NCT01125475 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 61

Last updated 2014-07-16

No results posted yet for this study

Summary

The primary objective is to determine adherence to Rebif® New Formulation administered by RebiSmart during 12 weeks of therapy in patients with RRMS.

Conditions

  • Relapsing Remitting Multiple Sclerosis (RRMS)

Interventions

DEVICE

RebiSmart

Treatment with Rebif New Formulation using RebiSmart.

Sponsors & Collaborators

  • Merck Serono Norway

    collaborator INDUSTRY

  • Smerud Medical Research International AS

    collaborator OTHER

  • Merck KGaA, Darmstadt, Germany

    lead INDUSTRY

Principal Investigators

  • Medical Director · Merck Serono Norway

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2012-03-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01125475 on ClinicalTrials.gov